10-Q: Chain Bridge I Q1 2026 Financial Results

Chain Bridge I reports a net loss of $436,659 for Q1 2026 while continuing to pursue a business combination with Phytanix Bio.

Summary

• Reported a net loss of $436,659 for the three months ended March 31, 2026, compared to a net loss of $363,640 in the same period of 2025.
• Operating expenses totaled $252,039, primarily driven by general and administrative costs.
• Cash balance as of March 31, 2026, was $136,637, with a working capital deficit of $1,060,576.
• The company maintains a trust account balance of $774,848 invested in U.S. treasury securities.
• Management has identified a material weakness in internal controls over financial reporting related to the review and reconciliation of liabilities and prepaid expenses.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to the going concern warning, delisting from a major exchange, and the significant working capital deficit.

Positives

• Continued support from the sponsor, Fulton AC, through ongoing monthly capital contributions to the trust account.
• Successfully regained compliance with Nasdaq listing requirements regarding public shareholder counts prior to delisting.
• Active pursuit of a business combination with Phytanix Bio remains the primary strategic focus.

Negatives

• The company was delisted from Nasdaq and now trades on the OTCID market.
• Reported a working capital deficit of over $1 million.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to liquidity constraints and the mandatory liquidation date.
• Material weakness in internal control over financial reporting remains unresolved.

Risks

• Failure to consummate a business combination by the November 15, 2026 deadline will result in liquidation.
• Potential for being deemed an unregistered investment company under the Investment Company Act of 1940.
• Limited liquidity and reliance on external financing to fund ongoing operations.
• Delisting from Nasdaq may negatively impact stock liquidity and investor interest.

Future Outlook

The company remains focused on consummating the business combination with Phytanix Bio. If the transaction is not completed by November 15, 2026, the company will be required to cease operations and liquidate.

Management Comments

• Management acknowledges that the liquidity condition and the mandatory liquidation date raise substantial doubt about the company's ability to continue as a going concern.
• The company is actively evaluating strategic options to regain compliance with listing standards and remains committed to transparency.

Industry Context

StockSavvy.ai notes that this filing reflects the typical distress and operational challenges faced by late-stage SPACs that have exhausted their initial timelines and are struggling with liquidity and regulatory compliance while attempting to close a de-SPAC transaction.

Comparison to Industry Standards

• The company's reliance on sponsor loans for working capital is consistent with other SPACs in the late stages of their lifecycle.
• The delisting from Nasdaq to OTC markets is a common outcome for SPACs that fail to meet continued listing requirements during the extension period.

Corporate Governance

Related Party Transactions

• Ongoing administrative services agreement with Fulton AC for $30,000 per month.
• Outstanding debt obligations to Fulton AC and other related parties.

Stakeholder Impact

• Shareholders face significant risk of liquidation if the business combination is not completed.
• Warrant holders face the risk of their holdings expiring worthless.

Next Steps

• Continue efforts to consummate the business combination with Phytanix Bio.
• Manage liquidity to fund operations through the November 15, 2026 deadline.
• Address material weakness in internal controls.

Key Dates

Recommendation

The company is a distressed SPAC with a going concern warning, a working capital deficit, and has been delisted from Nasdaq. The high probability of liquidation and the lack of operational revenue make this a high-risk, low-reward investment.

Keywords

SPAC, Chain Bridge I, Phytanix Bio, Business Combination, Going Concern, OTC, Financial Reporting